On the strength of the results, 4DMT is planning to start a phase 3 trial of the gene therapy by the end of the first quarter of 2025.
The data from the phase 2 PRISM study comes from a cohort of 51 patients with wet or neovascular AMD, a form of the disease where abnormal blood vessels grow in the back of the eye.
They all had severe disease and a high treatment burden with an average of 10 injections with Eylea (aflibercept), a widely-used VEGF inhibitor sold by Bayer and Regeneron, in the last 12 months. Two one-shot doses of 4D-150 are being tested in the study and compared to Eylea.
